What does a randomised trial tell us about prostate biopsy?

GU Cast | Urology Podcast

Innhold levert av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

9M ago 32:22

MP3•Episoder hjem

Needle through the rectum or needle through the skin?? Transrectal vs transperienal prostate biopsy is certainly a hot topic in prostate cancer, with the vast majority of men having their biopsy through the rectum rather than through the skin. It is quick, cheap and easy (for the urologist and the health system), but leaves the patient at risk of serious harm from infectious complications, at least according to historic reports.
Today Declan and Renu chat with Dr Jim Hu, Urologist at Cornell University in New York, and leader of the PREVENT trial, a randomised study of transrectal vs transperineal biopsy which has just been published in European Urology. We are also joined by Associate Professor Jeremy Grummet, Urologist at Alfred Health in Melbourne, and long-time advocate of transperineal biopsy. Did this trial finally establish transperineal as the new standard of care for men undergoing prostate biopsy?? Tune in to find out!
Even better on our YouTube channel
Links:
PREVENT trial in European Urology

159 episoder

#Science #Fitness #Medicine #Dr Renu Eapen #Professor Declan Murphy #Urology #Prostate Cancer #Kidney Cancer #Testis Cancer #Penile Cancer #Gu Oncology #Cancer #Podcasting Education #Professor Declan Murphy And Dr Renu Eapen